To access the webinar, you must be logged into your TxSCO account. If you do not have an account, you will need to create one by clicking on the green "register" bar on the right-hand side of the screen of the registration portal, then "login" and selecting the "create account" option. For assistance, please contact us.

Characterizing and Targeting a Tumor Immune Microenvironment in FGFR-Mutated Bladder Cancer

 

Novel immunotherapy drugs are used to treat advanced bladder cancer when chemotherapy is no longer working. However, only one in five patients responds to immunotherapy, likely due to biological differences in bladder cancer. Hear Dr. Andreev-Drakhlin—recipient of The ASCO Foundation 2020 Conquer Cancer Young Investigator Award— presents his research plans in using fibroblast growth factor receptor (FGFR) inhibitors for improving the effectiveness of immunotherapy for bladder cancer.

Presented by:
Alexander Andreev-Drakhlin, MD
Medical Oncology Fellow
University of Texas MD Anderson Cancer Center

VIEW ON-DEMAND RECORDING 

 
ACCCeLearning-OSS - 500x135

1801 Research Boulevard Suite 400
Rockville, MD 20850
Tel: 301.984.9496 | Fax: 301.770.1949
txsco.com
Email Us